Tye Soon Limited (SGX:BFU)
0.3300
0.00 (0.00%)
At close: Aug 8, 2025, 5:00 PM SGT
Intra-Cellular Therapies Revenue
In the year 2024, Tye Soon had annual revenue of 257.49M SGD with 1.19% growth. Tye Soon had revenue of 128.72M in the half year ending December 31, 2024, with 2.74% growth.
Revenue
257.49M
Revenue Growth
+1.19%
P/S Ratio
0.11
Revenue / Employee
3.22M
Employees
80
Market Cap
28.80M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 257.49M | 3.03M | 1.19% |
Dec 31, 2023 | 254.46M | 4.99M | 2.00% |
Dec 31, 2022 | 249.47M | 24.14M | 10.71% |
Dec 31, 2021 | 225.33M | 27.09M | 13.67% |
Dec 31, 2020 | 198.24M | -23.95M | -10.78% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
DBS Group Holdings | 22.10B |
Oversea-Chinese Banking Corporation | 13.72B |
Singapore Telecommunications | 14.15B |
United Overseas Bank | 13.32B |
Singapore Technologies Engineering | 11.28B |
Jardine Matheson Holdings | 45.30B |
Singapore Airlines | 19.54B |
Wilmar International | 91.96B |